Defence Therapeutics Inc. (DTC.CN)
Defence Therapeutics Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Vancouver, BC, CA. The stock last traded at $0.40, down 3.66% on the session, giving a market capitalisation of $29.9M. Its beta of 1.33 implies it has historically moved more than the broad market.
Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases. A cornerstone of its approach is the exclusive ACCUM™ technology, engineered to precisely and safely transport vaccine antigens or antibody-drug conjugates (ADCs) directly to their intended cellular targets. The company's development efforts span several key areas: novel dendritic cell vaccines for various cancers, protein-based vaccines addressing COVID-19 and other infectious ailments, and specialized antibody-drug conjugate products aimed at different cancer types. Defence Therapeutics Inc. adopted its current name in March 2020, having previously operated as Accum Therapeutics Inc.
Defence Therapeutics Inc. is most often compared with the following Healthcare names: